Company description

CRIS is a biotechnology company that focuses on the development of innovative medicines for the treatment of cancer and other rare diseases. Founded in 1999, the company has become a leader in the field of precision medicine, using cutting-edge technology to identify and target specific genetic mutations in cancer cells. Their flagship product, Elzonris, was approved by the FDA in 2018 for the treatment of a rare form of leukemia. In addition to their groundbreaking research and development efforts, CRIS is also committed to sustainability and operates a state-of-the-art, environmentally friendly facility in Massachusetts. The company is led by a team of experienced scientists and business executives, and has partnerships with major pharmaceutical companies and academic institutions. CRIS continues to push the boundaries of science in their quest to find new and effective treatments for cancer and other rare diseases, making them a promising and dynamic player in the biotech industry.